Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-03-09

Clinical Trial Update: Tecemotide (L-BLP25) in Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of Tecemotide (L-BLP25) for prostate cancer completed, with results posted in March 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tecemotide (L-BLP25)

Snippet

Sponsor: EMD Serono | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-03-09